BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, November 12, 2025
Home » Topics » Drug design, drug delivery and technologies, BioWorld

Drug design, drug delivery and technologies, BioWorld
Drug design, drug delivery and technologies, BioWorld RSS Feed RSS

Nobel Prize graphic with illustrations of Katalin Karikó and Drew Weissman
Infection

Perseverance on mRNA therapy research wins the 2023 Nobel Prize in Medicine after saving millions of lives

Oct. 2, 2023
By Mar de Miguel
Researchers who follow their instincts and achieve slow results while trying to break barriers have little support. They replace it with persistence. This is the story of Katalin Karikó and Drew Weissman. What was once a dream in their minds was later a success. Their work together for decades was essential to achieving mRNA vaccines, and their perseverance was rewarded today with the 2023 Nobel Prize in Medicine.
Read More
Mosaic illustration of a mouse
Neurology/Psychiatric

Genetic editing of individual cells points to late targets for developmental disorders

Sep. 28, 2023
By Mar de Miguel
A new gene editing method uses the CRISPR technique to modify the cells of an organ in vivo, creating a mosaic used to identify the effects of each altered gene. Scientists from the Swiss Federal Institute of Technology (ETH) in Zürich developed this technology called AAV-Perturb-seq, based on adeno-associated virus (AAV) to target, edit and analyze single-cell genetic perturbations.
Read More
Art concept for gene therapy research
Genetic/Congenital

Machine learning tool Alphamissense analyzes human mutations to predict diseases

Sep. 19, 2023
By Mar de Miguel
Proteome analysis with artificial intelligence has made it possible to create a catalog of all possible missense mutations in the human genome to predict diseases. The new Alphamissense tool from the technology company Google Deepmind, available online, will allow scientists to refine diagnoses and design more tailored treatment strategies for patients suffering from pathologies associated with these variants.
Read More
Cancer research illustration
Cancer

Multiple KRAS targeting strategies paving way for combination therapies

Aug. 25, 2023
By Mar de Miguel
KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating strategies to address other mutations and uses beyond non-small cell lung cancer (NSCLC) and colorectal cancer. If you can't bind KRAS to block it, use a glue or combine multiple weapons. This is the idea behind two new approaches that target cancers caused by this proto-oncogene.
Read More
Day 4 embryoid showing an inner epiblast-like domain that has apico-basal polarity
Drug Design, Drug Delivery & Technologies

New human embryonic models bring hope for insights, but also lots of brouhaha

June 28, 2023
By Mar de Miguel
The development of an embryo in its early stages involves a series of processes in which cells interact and organize to form tissues. In humans, these stages are studied with animal models, stem cells and cell aggregates that mimic natural development phases, or with human embryos, depending on their availability and a strict protocol. Now, in back-to-back papers published online in Nature, scientists from Yale University and the University of Cambridge have two new embryonic models formed from human stem cells to study development after embryo implantation in the uterus.
Read More
Illustration of pancreas
Endocrine/Metabolic

Gene therapy to reverse T2D shows proof of concept at ASGCT

May 18, 2023
By Mar de Miguel
The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose of the gene therapy against type 2 diabetes (T2D) and obesity that Fractyl Health Inc. is developing. Scientists from the Lexington, Mass.-based company have designed a strategy based on glucagon-like peptide-1 (GLP-1) to transform pancreatic cells and reverse the disease.
Read More
Felix Wong, co-founder and CEO, Integrated-Biosciences
Newco news

Integrated Biosciences trains neural networks to identify novel senolytic drugs

May 4, 2023
By Cormac Sheridan
Integrated Biosciences Inc., an early-stage startup that is combining synthetic biology and machine learning in the hunt for drugs that tackle cell senescence, has demonstrated its capabilities in a newly published study in Nature Aging on May 4, 2023, which employed artificial intelligence to identify three novel compounds that are highly selective for Bcl-2 and that exhibit favorable medicinal chemistry profiles.
Read More
Fat targeting illustration
Endocrine/Metabolic

Nanomaterial allows location-specific fat targeting

Dec. 7, 2022
By Anette Breindl
The positively charged nanoparticle polyamidoamine generation 3 (P-G3) can be specifically targeted to either visceral or subcutaneous fat, and affects both types of fat in different ways, researchers from Columbia University reported in two papers recently published. The studies, published online in Nature Nanotechnology on Dec. 1, 2022, and in Biomaterials on Nov. 28, 2022, are both “a conceptual advance” and “quite amenable to translation,” co-corresponding author Kam Leong told BioWorld.
Read More
The Combat of Rama and Ravana.
Cancer

ENA 2022: Mutant specific or target selective, that is the question for drug development

Oct. 27, 2022
By Mar de Miguel and Anette Breindl
Diwali, the Festival of Light, marks different events depending on where it is celebrated. In some areas of India, it marks the return of Lord Rama to his birthplace of Ayodhya after defeating the demon Ravana. For Vivek Subbiah, associate professor at the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine of the MD Anderson Cancer Center, the story of how Rama defeated Ravana has parallels in drug discovery. Ravana had 10 heads, and when one was cut off, it grew back. Rama defeated Ravana by means of a magic arrow that entered through the demon’s navel.
Read More
Concept illustration of click chemistry.
Drug Design, Drug Delivery & Technologies

Promoting attachments nets 2022’s Nobel Prize in Chemistry

Oct. 5, 2022
By Anette Breindl and Mar de Miguel
The 2022 Nobel Prize in chemistry was awarded to Carolyn Bertozzi of Stanford University, to Morten Meldal of the University of Copenhagen, and – for the second time – to Barry Sharpless of The Scripps Research Institute “for the development of click chemistry and bioorthogonal chemistry.”

Click chemistry, the Nobel Committee’s Olof Ramström told reporters while announcing the prize, “is almost like it sounds – it’s all about linking different molecules.”

He likened click chemistry to a seatbelt buckle, whose interlocking parts can be attached to many different materials, linking them by snapping the two parts of the buckle together.

“The problem was to find good chemical buckles,” Ramström said – chemicals that “will easily snap together, and importantly, they won’t snap with anything else.”
Read More
Previous 1 2 3 4 5 6 7 8 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Nov. 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Nov. 12, 2025.
  • Female doctor and patient

    Could restricting diversity efforts stall women’s health research?

    BioWorld
    Recent progress in redressing the historical underfunding and neglect of women’s health could be undermined by the backlash against diversity, equity and...
  • Man falling asleep in car

    Alkermes’ alixorexton hits endpoints in narcolepsy phase II

    BioWorld
    Alkermes plc’s placebo-controlled phase II study of alixorexton in treating narcolepsy type 2 (NT2) hit its dual primary endpoints, producing statistically...
  • Pazdur ‘optimal fit’ to lead FDA’s CDER

    BioWorld
    In reaching within to name 26-year FDA veteran Richard Pazdur as the next CDER director, FDA Commissioner Marty Makary likely chose the best possible person to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing